European Journal of Clinical Pharmacology

, Volume 75, Issue 10, pp 1469–1470 | Cite as

Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS)

  • Charlotte L. StokesEmail author
  • Jan Schjøtt
Letter to the Editor

The Norwegian network of drug information centres (RELIS) has developed a full-text, searchable question (Q)-answering (A) database with nearly 50,000 Q/A pairs. The RELIS database is used to document decision support in complex clinical cases provided by clinical pharmacologists and pharmacists with written responses within a requested time frame [1, 2]. Selected Q/A pairs are published online in Norwegian on as open access and are freely available to healthcare professionals. Answers considered as not having any general interest, or questions that are so specific there is a risk the patient can be identified, are only available for the RELIS staff. All Q/A pairs are indexed by the staff, and searchable through selection of drugs (e.g., generic, ATC-code), categories (e.g., adverse effects, interactions), and text words (e.g., dependency, misuse). The search function used by the staff includes Boolean operators (e.g., AND/OR/NOT) to allow combined searches [1, 2].



Database Decision support Disproportionality analysis Drug information centre Drug safety 


Authors’ individual contributions

The manuscript was drafted by the idea of Jan Schjøtt, who is also responsible for the statistics. Charlotte L. Stokes has contributed in writing, reference search, and submission.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Schjøtt J, Reppe LA, Roland PD,Westergren T (2012) A question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open 2:e000642Google Scholar
  2. 2.
    Schjøtt J. (2017) Benefits of a national network of drug information centres: RELIS. Eur J Clin Pharmacol. 73(1):125–126.Google Scholar
  3. 3.
    Harpaz R, DuMouchel W, Shan NH, Mdigan D, Ryan P, Friedman C (2012) Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 91(6):1010–1021CrossRefGoogle Scholar
  4. 4.
    Ventola CL (2018) Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T 43(6):340–351Google Scholar
  5. 5.
    Anon (2016) Quetiapine: misuse and abuse. Prescrire Int 25(169):68Google Scholar
  6. 6.
    Chiappini S, Schifano F (2018) Is there a potential of misuse for quetiapine?: literature review and analysis of the European Medicines Agency/European Medicines Agency adverse drug reactions’ database. J Clin Psychopharmacol 38(1):72–79Google Scholar
  7. 7.
    Lee J, Pilgrim J, Gerostamoulos D, Robinson J, Wong A (2018) Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia. Drug Alcohol Depend 187:95–99CrossRefGoogle Scholar
  8. 8.
    Evoy KE, Morrison MD, Saklad SR (2017) Abuse and misuse of pregabalin and gabapentin. Drugs 77(4):403–426CrossRefGoogle Scholar
  9. 9.
    Schifano F (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28(6):491–496CrossRefGoogle Scholar
  10. 10.
    Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27(12):1185–1215CrossRefGoogle Scholar
  11. 11.
    Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M (2019) Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol.
  12. 12.
    Böhm R. Primer on disproportionality analysis. Version: 2018-10-16. Accessed 10th April 2019

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical Biochemistry and PharmacologyHaukeland University HospitalBergenNorway
  2. 2.Department of Clinical Science, Faculty of Medicine and DentistryUniversity of BergenBergenNorway

Personalised recommendations